Ocugen (OCGN) Non-Current Assets (2014 - 2026)
Ocugen's (OCGN) quarterly Non-Current Assets came in at $18.4 million in Q1 2026, down 10.45% YoY from $20.5 million in Q1 2025, and down 4.29% on a QoQ basis from $19.2 million in Q4 2025.
Ocugen (OCGN) Non-Current Assets (2014 - 2026) Analysis & Trends
Ocugen (OCGN) has 13 years of Non-Current Assets data on file, last reported at $18.4 million in Q1 2026.
- Quarterly Non-Current Assets fell 10.45% year-over-year to $18.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $78.2 million (down 7.4% YoY) and the FY2025 annual result came in at $19.2 million, down 7.63% from the prior year.
- Non-Current Assets retreated to $18.4 million in Q1 2026, from $19.2 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $21.9 million in Q2 2024 to a low of $3.7 million in Q1 2022.
- A 5-year average of $16.6 million and a median of $19.2 million in 2025 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets soared 225.52% — and 2026, when it fell 10.45%.
- Tracing OCGN's Non-Current Assets over 5 years: stood at $10.1 million in 2022, then surged by 112.78% to $21.6 million in 2023, then decreased by 3.78% to $20.8 million in 2024, then fell by 7.63% to $19.2 million in 2025, then retreated by 4.29% to $18.4 million in 2026.
- The last three Non-Current Assets figures came in at $18.4 million (Q1 2026), $19.2 million (Q4 2025), and $20.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Ocugen | 457.71 Mn | 357.61 Mn | - | 17.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.49 Mn |
| Mar 31, 2026 | 18.35 Mn |
| Dec 31, 2025 | 19.18 Mn |
| Sep 30, 2025 | 19.96 Mn |
| Jun 30, 2025 | 20.71 Mn |
| Mar 31, 2025 | 20.50 Mn |
| Dec 31, 2024 | 20.76 Mn |
| Sep 30, 2024 | 21.26 Mn |
| Jun 30, 2024 | 21.93 Mn |
| Mar 31, 2024 | 21.80 Mn |
| Dec 31, 2023 | 21.58 Mn |
| Sep 30, 2023 | 18.13 Mn |
| Jun 30, 2023 | 15.52 Mn |
| Mar 31, 2023 | 11.90 Mn |
| Dec 31, 2022 | 10.14 Mn |
| Sep 30, 2022 | 8.74 Mn |
| Jun 30, 2022 | 7.52 Mn |
| Mar 31, 2022 | 3.70 Mn |
| Dec 31, 2021 | 3.12 Mn |
| Sep 30, 2021 | 2.86 Mn |